eISSN: 2084-9869
ISSN: 1233-9687
Polish Journal of Pathology
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
vol. 75
Original paper

A study on expression of programmed death ligand-1 in small cell lung carcinoma and correlation with clinicopathological parameters

Sudha Sudha
Saumya Shukla
Nuzhat Husain
Hemant Kumar
Rahul Kumar Pandey
Surya Kant

  1. Department of Pathology, Dr. Ram Manohar Lohia Institute of Medical Sciences, Lucknow-UP, India
  2. Department of Respiratory Medicine, Dr. Ram Manohar Lohia Institute of Medical Sciences, Lucknow-UP, India
  3. Department of Respiratory Medicine, King George’s Medical University, Lucknow-UP, India
Pol J Pathol 2024; 75 (1): 25-35
Online publish date: 2024/03/15
View full text Get citation
PlumX metrics:
Small cell lung carcinoma (SCLC) is characterized by rapid growth and an aggressive clinical course. Standard therapy regimes have limited effects on disease course; therefore the prognosis of SCLC is poor. In the current study, the frequency of programmed death ligand 1 (PD-L1) expression in SCLC and its correlation with clinico-pathological features were evaluated.

The study included 100 cases of SCLC wherein testing for PD-L1 was done with the SP263 clone on the Ventana benchmark XT system. Cases with > 1% PD-L1 expression in tumour cells or immune cells were categorized as positive.

PD-L1 expression was identified in 14% of cases using the cut-off of ≥ 1%. The tumour proportion score was 10% and the immune proportion score was 9.78% using a cut-off of ≥ 1%. PD-L1 positive expression was more frequent in the male population with age > 40 years. All the patients with positive PD-L1 expression were smokers. In the PD-L1 positive group, presence of necrosis was identified in 71.4% of cases and when compared with the PD-L1 negative subgroup this finding was statistically significant (p = 0.010).

Personalized targeted therapy for cases of SCLC is still under evaluation. The use of immunotherapeutic targets, such as PD-L1, may help to define a new treatment strategy for SCLC. Development of new treatment strategies may improve prognosis and survival.

immunotherapy, small cell lung carcinoma, programmed death ligand-1

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.